

Focus on Drugs in the Pipeline

HEMONC TODAY's 11th Annual Guide to Drugs in the Pipeline

Twice a year HEMONC TODAY publishes a Drugs in the Pipeline chart of drugs in the phase-2 or phase-3 status of development. This chart features drugs in the oncology arena. Information was taken from Pharmaceutical Research and Manufacturers of America, corporate websites and the databases of HEMONC TODAY.

Generic name	Indication	Development status
1018 ISS (Dynavax)	non-Hodgkin's lymphoma	phase 2
1203486A (GlaxoSmithKline)	malignant melanoma	phase 2
¹³¹ I-TM-601 (TransMolecular)	recurrent high-grade glioma	phase 2
1363089 (GlaxoSmithKline)	gastric cancer, head and neck cancer, papillary renal cell carcinoma, squamous cell carcinoma	phase 2
1572932A (GlaxoSmithKline)	non-small cell lung cancer	phase 3
184072 (GlaxoSmithKline)	colon cancer, hematologic malignancies	phase 2
2132231A (GlaxoSmithKline)	malignant melanoma	phase 3
3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine, Vion)	leukemia, NSCLC, pancreatic cancer, prostate cancer	phase 2
3F8 mAb (United Therapeutics)	central nervous system cancer, neuroblastoma, leptomeningeal cancer	phase 2
A 007 (Tigris)	anal intraepithelial neoplasia, cervical intraepithelial neoplasia	phase 2
A6 (Angstrom)	ovarian cancer	phase 2
abagovoab (Menarini)	ovarian cancer	phase 2/3
ABIO05/01 (Abiogen)	chronic myeloid leukemia	phase 2
ABI 007 (Abraxane, Abraxis)	malignant melanoma, ovarian cancer, prostate cancer NSCLC	phase 2 phase 3
ABR-215050 (Active Biotech)	prostate cancer	phase 2
ABT-510 (Abbott)	lung cancer, lymphoma, RCC, sarcoma, solid tumors	phase 2
ABT-751 (Abbott)	breast cancer, colorectal cancer, NSCLC, RCC	phase 2
ABT 869 (Genentech)	hepatocellular carcinoma, metastatic breast cancer, metastatic colorectal cancer, NSCLC, RCC	phase 2
ABT 888 (Abbott)	malignant melanoma	phase 2
adecatumumab (EMD)	breast cancer, prostate cancer	phase 2
aderbasib (Incyte)	breast cancer	phase 2
ADH-1 (Exherin, Adherex)	solid tumors	phase 2
AE 37 (Antigen Express)	breast cancer	phase 2
AEG 35156 (Idera)	acute myeloid leukemia	phase 2
afimoxifene (TamoGel, Ascend)	breast cancer	phase 2
aflibercept (Sanofi-Aventis, Regeneron)	colorectal cancer, NSCLC, ovarian cancer, pancreatic cancer, prostate cancer	phase 3
AG-14699 (Pfizer)	breast cancer, ovarian cancer	phase 2
agatolimod (ProMune, Pfizer)	NSCLC	phase 2
AGS-003 (Argos Therapeutics)	renal cancer	phase 2
AKR-501 (MGI)	thrombocytopenia	phase 2
albumin-bound paclitaxel (Abraxis Bio Science)	ovarian cancer, prostate cancer, malignant melanoma NSCLC	phase 2 phase 3
aldesleukin (Proleukin, Novartis)	AML, NHL	phase 3
alemtuzumab (Campath, Bayer)	chronic lymphocytic leukemia	phase 2
alendronic acid (Fosamax, Merck)	bone loss	phase 2
alvocidib (Sanofi Aventis)	CLL	phase 3
AMG 102 (Amgen)	glioma, RCC	phase 2
AMG 386 (Amgen)	breast cancer, gastric cancer, fallopian tube cancer, ovarian cancer, peritoneal cancer, RCC	phase 2
AMG 479 (Amgen)	breast cancer, cervical cancer, lung cancer, sarcoma	phase 2
AMG 655 (Amgen)	pancreatic cancer	phase 2
AMG 951 (Amgen)	NHL	phase 2
amolmogene (MGI)	cervical dysplasia	phase 2/3
aminolevulinic acid (Levulan PDT, DUSA)	cervical intraepithelial neoplasia	phase 2
amrubicin (Pharmion)	small cell lung cancer	phase 3
amonafile (Quinamed, ChemGenex)	breast cancer, ovarian cancer, prostate cancer	phase 2
amonafile maleate (Xanafide, Xanthus)	AML	phase 3
anti-idiotypic cancer vaccine (105AD7, Onyva)	prostate cancer	phase 2
anti-tenascin mAb 81C6-I-131 (Neuradiab, Bradmer)	glioblastoma	phase 3
AP 5346 (Access)	head and neck cancer	phase 2
apaziquone (EOquin, Spectrum)	bladder cancer	phase 3



Focus on Drugs in the Pipeline

Generic name	Indication	Development status
apomab (Genentech)	NHL, NSCLC	phase 2
apricoxib (Capoxigem, Tragara)	NSCLC, pancreatic cancer	phase 2
AR-726 (Antigenics)	colorectal cancer	phase 2
arsenic trioxide (Trisenox, Cephalon)	AML multiple myeloma	phase 3 phase 2
arzoxifene (Eli Lilly)	breast cancer endometrial cancer, ovarian cancer, peritoneal cancer	phase 3 phase 2
AS 1402 (Anticoma)	breast cancer	phase 2
AS 1411 (Antisoma)	AML, RCC	phase 2
AS 1413 (Antisome)	AML	phase 3
AT 101 (Ascenta)	CLL, NHL, NSCLC, prostate cancer, SCLC	phase 2
atacept (EMD Serono)	multiple myeloma	phase 2
atiprimod (Callisto)	carcinoid tumor	phase 2
ATN-224 (Attenuon)	malignant melanoma, prostate cancer	phase 2
atrasentan (Xinlay, Abbott)	brain cancer, lung cancer, ovarian cancer, RCC	phase 2
autologous dendritoma vaccine (Melaxin, Oncolix)	malignant melanoma	phase 2
AVE1642 (Sanofi-Aventis)	hormonal-sensitive breast cancer	phase 2
AVE8062 (Sanofi-Aventis)	sarcoma	phase 3
AVN-944 (Avalon)	pancreatic cancer	phase 2
axitinib (Pfizer)	AML, breast cancer, colorectal cancer, malignant melanoma, myelodysplastic syndromes, NSCLC, RCC pancreatic cancer, thyroid cancer	phase 2 phase 3
azacitidine (Vidaza, Celgene)	NHL, Hodgkin's lymphoma, prostate cancer	phase 2
AZD 0530 (AstraZeneca)	bone cancer, colorectal cancer, hematologic malignancies, prostate cancer, solid tumors	phase 2
AZD 1152 (AstraZeneca)	hematologic malignancies	phase 2
AZD 2281 (AstraZeneca)	breast cancer, ovarian cancer	phase 2
AZD 4054 (AstraZeneca)	hormone-refractory metastatic prostate cancer	phase 3
AZD 4877 (AstraZeneca)	hematologic malignancies, solid tumors	phase 2
AZD 6244 (AstraZeneca)	AML, colorectal cancer, hepatocellular carcinoma, malignant melanoma, multiple myeloma NSCLC, ovarian cancer, pancreatic cancer, solid tumors, thyroid cancer	phase 2
AZM475271 (AstraZeneca)	hematological malignancies	phase 2
batabulin (Amgen)	hepatocellular carcinoma	phase 3
BAY 73-4506 (Bayer)	kidney cancer	phase 2
B-cell lymphoma vaccine (BiovaxID, Accentia)	NHL	phase 3
BC-819 (BioCancell Therapeutics)	bladder cancer	phase 2
bectumomab (Immunomedics)	NHL	phase 2
belagenpumatucel-L (Lucanix, NovaRx)	NSCLC	phase 2
belinostat (Topo Target USA)	AML, bladder cancer, cutaneous T-cell lymphoma, liver, lung, mesothelioma, MDS, NHL, ovarian cancer, peripheral T-cell lymphoma, thymoma	phase 2
bendamustine (Treanda, Cephalon)	multiple myeloma	phase 2
berubicin (Reata)	brain metastasis	phase 2
beta lapachone (ARQ 501; ArQule, Roche)	head and neck cancer, leiomyoma, pancreatic cancer	phase 2
bevacizumab (Avastin, Genentech)	central nervous system metastasis, multiple myeloma, NSCLC, ovarian cancer, SCLC carcinoid cancer, colon cancer, colorectal cancer, large B-cell lymphoma, gastric cancer, gastrointestinal stromal tumors, glioblastoma, head and neck cancer, hormone-refractory prostate cancer, NSCLC, ovarian cancer, RCC	phase 2 phase 3
bexarotene (Targretin, Eisai)	solid tumors	phase 2
BIBF 1120 (Boehringer Ingelheim)	NSCLC	phase 3
BIBW 2992 (Boehringer Ingelheim)	breast cancer, head and neck cancer, NSCLC	phase 2
BMS-844203 (Bristol-Myers Squibb)		phase 2
bleomycin (MedPulser, Inovio)	head and neck cancer	phase 3
BLP25 liposomal cancer vaccine (Stimuvax, Oncothyreon)	NSCLC	phase 3
BNP 1350 (BioNumerik)	brain cancer, malignant melanoma, NSCLC ovarian cancer	phase 2 phase 3
bortezomib (Velcade, Millennium)	NHL NSCLC	phase 3 phase 2
bosutinib (Wyeth)	breast cancer	phase 2
brain cancer vaccine (DCVax-Brain, Northwest)	glioblastoma	phase 2

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
brivanib (Bristol-Myers Squibb)	colorectal cancer, hepatocellular carcinoma	phase 3
brotallicin (Cell Therapeutics)	solid tumors	phase 2
BSI-201 (BiPar Sciences)	breast cancer	phase 2
cabazitaxel (Sanofi-Aventis)	prostate cancer	phase 3
cancer vaccine (OncoVAX, Vaccinogen)	colorectal cancer	phase 2
canertinib (Pfizer)	NSCLC	phase 2
canfosfamide (Telcyta, Telik)	breast cancer, colorectal cancer NSCLC, ovarian cancer	phase 2 phase 3
capecitabine (Xeloda, Roche)	pancreatic cancer, RCC	phase 2
carfilzomib (Proteolix)	multiple myeloma, solid tumors	phase 2
casopitant (Rezonic, GlaxoSmithKline)	nausea and vomiting	phase 3
catumaxomab (Fresenius)	malignant ascites, ovarian cancer	phase 2
CB7630 (Cougar)	prostate cancer	phase 2
CBP501 (Millennium Pharmaceuticals)	mesothelioma	phase 2
CC 8490 (Celgene)	glioblastoma	phase 2
CDB-4124 (Repro)	uterine leiomyoma	phase 3
CDX-110 (Avant)	glioblastoma	phase 2/3
cediranib (Recentin, AstraZeneca)	breast cancer, NSCLC	phase 2 phase 3
celecoxib (Celebrex, Pfizer)	bladder cancer, colorectal cancer melanoma NSCLC, prostate cancer	phase 3 phase 2/3 phase 2
cenersen (Aezea, Eleos)	hematologic malignancies	phase 2
cetuximab (Erbix; Bristol-Myers Squibb, ImClone)	colorectal cancer, esophageal cancer, head and neck cancer, lung cancer, NSCLC, pancreatic cancer, prostate cancer	phase 2
cetuximab (Eli Lilly)	colorectal cancer, esophageal cancer, lung cancer	phase 3
CGC-11047 (Progen)	prostate cancer	phase 2
cilengitide (Merck)	glioblastoma, prostate cancer	phase 2
cintredekin besudotox (IL13-PE38QQR, Neopharm)	glioblastoma	phase 3
cisplatin liposomal (Transave)	lung cancer	phase 2
clofarabine (Clolar, Genzyme)	AML	phase 2
CNF-2024 (Biogen Idec)	gastrointestinal stromal tumor	phase 2
CNTO 95 (Centocor)	prostate cancer	phase 2
CNTO 328 (Centocor)	multiple myeloma, prostate cancer	phase 2
combrestatin (OXIGENE)	breast cancer, NSCLC, ovarian cancer thyroid cancer	phase 2 phase 2/3
conatumumab (Amgen)	colorectal cancer	phase 2
contusogene ladenovec (Advexin, Introgen)	breast cancer, NSCLC head and neck cancer	phase 2 phase 3
corticoelin (Xerecept, Celtic)	peritumoral brain edema	phase 3
cositecan (Karenitecin, BioNumerik Pharmaceuticals)	NSCLC, malignant melanoma, ovarian cancer	phase 2
CP 4055 (Elacyt, Clavis)	AML, malignant melanoma	phase 2
CP-751871 (Pfizer)	breast cancer, prostate cancer, sarcoma	phase 2
CPX-1 (Celator)	colorectal cancer	phase 2
CPX-351 (Celator)	AML	phase 2
CR011-vcMMAE (CurGen)	breast cancer, malignant melanoma	phase 2
CS-1017 (Daiichi Sankyo)	NSCLC	phase 2
CT-011 (Genentech)	B-cell lymphoma	phase 2
CT 2106 (Cell Therapeutics)	solid tumors	phase 2
CT-322 (Bristol-Myers Squibb)	glioblastoma	phase 2
dacetuzumab (Genentech, Seattle)	diffuse large B-cell lymphoma	phase 2
darinaparsin (Ziopharm)	hematologic malignancies	phase 2
dasatinib (Sprycel, Bristol-Myers Squibb)	breast cancer, prostate cancer	phase 2
decitabine (Dacogen, MGI)	AML	phase 3
deforolimus (Ariad, Merck)	breast cancer, hematologic malignancies, prostate cancer, NSCLC, endometrial cancer sarcoma	phase 2 phase 3
degarelix (Ferring)	prostate cancer	phase 3

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
denenickin (ZymoGenetics)	kidney cancer	phase 2
denileukin difitox (Ontak, Eisai)	peripheral T-cell lymphoma	phase 2
denosumab (Amgen)	bone loss/damage, prevention of bone metastasis	phase 3
diflomotecan (Biomesure, Roche)	SCLC	phase 2
DMXAA (Novartis)	prostate cancer	phase 2
docetaxel (Taxotere, Sanofi Aventis)	pediatric cancers	phase 3
doxorubicin (Dalcath Systems)	liver cancer	phase 2
DR5-targeting proapoptotic receptor agonist (Apomab, Genentech)	NHL, NSCLC	phase 2
dulanermin (Genentech)	NHL, NSCLC	phase 2
dutasteride (Avodart, GlaxoSmithKline)	prostate cancer prevention, prostate intraepithelial neoplasia	phase 3
eribulin mesylate (E7389, Eisai)	breast cancer NSCLC, prostate cancer, sarcoma	phase 2/3 phase 2
E7080 (Eisai)	thyroid cancer	phase 2
E75 cancer vaccine (NeuVax, Aphera)	breast cancer	phase 2
EC 17 (Endocyte)	kidney cancer	phase 2
EC 145 (Endocyte)	endometrial cancer, ovarian cancer	phase 2
ecromeximab (Life Sciences)	malignant melanoma	phase 2
edotecarin (Pfizer)	colorectal cancer	phase 3
elacytarabine (Elacyt, Clavis)	AML, malignant melanoma, ovarian cancer	phase 2
elesclomol (GlaxoSmithKline, Synta)	malignant melanoma NSCLC, sarcoma	phase 3 phase 2
elsamitucin (Spectrum)	NHL	phase 2
EMD 273063 (Lexigen)	malignant melanoma, neuroblastoma	phase 2
enzastaurin (Eli Lilly)	breast cancer, NSCLC, ovarian cancer, pancreatic cancer diffuse large B-cell lymphoma, glioblastoma, NHL	phase 2 phase 3
epiratuzumab (LymphoCide, Immunomedics)	NHL, pediatric acute lymphocytic leukemia	phase 2
eribulin mesylate (Eisai)	NSCLC, ovarian cancer, prostate cancer	phase 2
erlotinib (Tarceva; Genentech, OSI)	glioblastoma NSCLC	phase 2 phase 3
everolimus (Certican, Novartis)	neuroendocrine tumors RCC	phase 2 phase 2/3
exatecan (Daiichi Sankyo)	ovarian cancer, peritoneal cancer, solid tumors pancreatic cancer	phase 2 phase 3
exemestane (Aromasin; Pfizer)	breast cancer prevention	phase 3
ezatiostat (Telintra, Telik)	MDS	phase 2
falimarev (PANVAC-VF, Therion)	pancreatic cancer	phase 3
farletuzumab (Eisai)	ovarian cancer	phase 2
finasteride (Proscar, Merck)	prostate cancer	phase 3
forodesine (Fodosine, BioCryst)	CLL, T-cell lymphoma cutaneous T-cell lymphoma	phase 2 phase 3
fosbretabulin (Zybrex, OXIGENE)	NSCLC, ovarian cancer, thyroid cancer	phase 2
fostamatinib (Rigel)	B-cell lymphoma, T-cell lymphoma	phase 2
GA101 (Genentech)	hematologic malignancies, NHL	phase 2
galactomannan (Davanat, PRO-Pharmaceuticals)	bile duct cancer, biliary cancer, colorectal cancer	phase 2
galiximab (Biogen Idec)	NHL	phase 3
GCS-100 (Prospect)	CLL	phase 2
gefitinib (Iressa, AstraZeneca)	bladder cancer, glioblastoma solid tumors	phase 2 phase 3
gemcitabine (Gemzar, Eli Lilly)	colorectal cancer, head and neck cancer, malignant melanoma, sarcoma, SCLC	phase 2
GI-4000 (GlobelImmune)	NSCLC	phase 2
glufosamide (Threshold)	breast cancer, sarcoma, SCLC pancreatic cancer	phase 2 phase 3
GRNVAC1 (Argos)	AML	phase 2
GTI 2040 (Lorus)	AML, breast cancer, colorectal cancer, RCC	phase 2
GV-1001 (Pharmexa)	pancreatic cancer	phase 3
hedgehog pathway inhibitor (Genentech)	basal cell carcinoma, colorectal cancer, ovarian cancer	phase 2
hematopoietic stem cell therapy (StemEx; Gamida Cell, Teva)	hematologic malignancies	phase 2/3

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
HER2-antigen specific cancer immunotherapeutic (GlaxoSmith-Kline)	brain cancer	phase 2
histamine dehydrochloride (Ceplene, EpiCet)	AML	phase 3
HuN901-DM1 (ImmunoGen)	SCLC	phase 2
ibandronic acid (Boniva, Roche)	malignant hypercalcemia	phase 3
idarubicin (Idamycin, Pfizer)	multiple myeloma, NHL	phase 3
IDM-2101 therapeutic, multiepitope vaccine (IDM)	NSCLC	phase 2
idronoxil (Marshall Edwards)	cervical cancer, fallopian tube cancer, vulvovaginal cancer ovarian cancer	phase 2 phase 3
iodine-labeled metaiodobenzylguanidine (Azedra, Molecular Insight Pharmaceuticals)		phase 2
imatinib (Gleevec, Novartis)	fibroma glioblastoma, prostate cancer	phase 2 phase 2/3
IMC-1121B (Lilly, ImClone)	breast cancer, solid tumors malignant melanoma, RCC	phase 3 phase 2
IMC-11F8 (ImClone)	solid tumors	phase 2
IMC-A12 (Lilly, ImClone)	colorectal cancer, solid tumors, prostate cancer	phase 2
imexon (Amplimexon, AmpliMed)	pancreatic cancer	phase 2
IMGN-242 (ImmunoGen)	metastatic gastric cancer	phase 2
IMGN-901 (ImmunoGen)	SCLC	phase 2
IMO 2055 (IMOXine; Idera, Merck)	RCC	phase 2
INCB 18424 (Incyte)	multiple myeloma, prostate cancer	phase 2
INCB 7839 (Incyte)	breast cancer, solid tumors	phase 2
INGN 225 (Introgen)	SCLC	phase 2
INGN 241 (Introgen)	head and neck cancer malignant melanoma	phase 3 phase 2
inhaled doxorubicin (Zivena)	lung cancer	phase 2
INNO-206 (Innovive)	SCLC	phase 2
INOC 002 (Avantogen)	colorectal cancer	phase 2
inotuzumab ozogamicin (UCB, Wyeth)	NHL	phase 3
ipilimumab (Bristol-Myers Squibb, Medarex)	adjuvant melanoma, malignant melanoma solid tumors	phase 3 phase 2
iratumumab (Medarex)	Hodgkin's lymphoma, NHL	phase 2
irinotecan (Camptosar, Pfizer)	pancreatic cancer prostate cancer	phase 3 phase 2
irofulven (MGI)	hormone-refractory prostate cancer	phase 2/3
IRX 2 (IRX)	head and neck cancer	phase 2
ispinesib (GlaxoSmithKline)	breast cancer, colorectal cancer, NSCLC, RCC, solid tumors	phase 2
IT-101 (Calando)	lymphoma, ovarian cancer	phase 2
ixabepilone (Ixempra, Bristol-Myers Squibb)	pancreatic cancer, prostate cancer	phase 2
JX-594 (Jennerex)	hepatocellular carcinoma	phase 2
KRX-0402 (Keryx)	brain cancer, glioblastoma, glioma, multiple myeloma, sarcoma	phase 2
lanreotide (Somatuline Autogel, Tercica)	neuroendocrine tumors	phase 3
lapatinib (Tykerb, GlaxoSmithKline)	brain metastasis, gastric cancer, head and neck cancer solid tumors	phase 3 phase 2
laromustine (Vion)	AML, glioma, SCLC	phase 2
larotaxel (Sanofi Aventis)	bladder cancer, pancreatic cancer breast cancer	phase 3 phase 2
lenalidomide (Revlimid, Celgene)	CLL AML, CNS cancer, glioblastoma, mantle cell lymphoma, myelofibrosis, NHL, prostate cancer, solid tumors multiple myeloma	phase 2/3 phase 2 phase 3
LEP-ETU (NeoPharm)	breast cancer	phase 2
LE-SN38 (NeoPharm)	colorectal cancer	phase 2
lestaurtinib (Cephalon)	AML, multiple myeloma	phase 2
leukemia vaccine (GVAX Leukemia, Cell Genesys)	AML, chronic myeloid leukemia	phase 2
leukocyte interleukin (Multikine, CEL-SCI)	cervical cancer, cervical dysplasia, head and neck cancer	phase 2
leuprorelin depot (Abbott)	prostate cancer	phase 3
lintuzumab (PDL BioPharma, Seattle)	AML	phase 2
liposomal cisplatin (Transave)	lung cancer	phase 2

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
liposomal doxorubicin (Doxil, OrthoBiotech)	breast cancer, sarcoma hepatocellular carcinoma, mesothelioma, NSCLC, prostate cancer	phase 3 phase 2
liposomal doxorubicin (Myocet, Sopherion)	breast cancer NHL	phase 3 phase 2
lonafarnib (Sarasar, Schering-Plough)	breast cancer, leukemia, pancreatic cancer, solid tumors MDS	phase 2 phase 3
LOR-2040 (Lorus Therapeutics)	AML, breast cancer, colorectal cancer	phase 2
LTSDDEL (Thermodox, Celsion)	hepatocellular carcinoma	phase 3
lucanthone (Spectrum)	glioma	phase 2
lumiliximab (Biogen Idec)	CLL	phase 2/3
LY 2127399 (Eli Lilly)	multiple myeloma	phase 2
LY 355703 (Eli Lilly)	NSCLC	phase 2
LY 573636 (Eli Lilly)	fallopian tube cancer, malignant melanoma, ovarian cancer, peritoneal cancer	phase 2
mage-3 recombinant phamacine (GlaxoSmithKline)	melanoma NSCLC	phase 2 phase 3
mage-A3 ASCI (GlaxoSmithKline)	melanoma, NSCLC	phase 3
mapatumumab (Human Genome Sciences)	multiple myeloma, NSCLC	phase 2
masitinib (AB Science USA)	gastrointestinal stromal tumor, mastocytosis, pancreatic cancer	phase 3
MCC/HA (Bioniche)	bladder cancer	phase 3
melanoma vaccine (M-Vax, Avax)	malignant melanoma	phase 3
melanoma vaccine (Uvidem, IDM)	malignant melanoma	phase 2
mepacrine (Cleveland BioLabs)	prostate cancer	phase 2
MER-101 (Merrion)	bone cancer	phase 2
methyl aminolevulinate (Metvixia, PhotoCure)	basal cell cancer	phase 3
MetMAb (Genentech)	NSCLC	phase 2
MGCD 0103 (Celgene, MethylGene)	AML, B-cell lymphoma, CLL, Hodgkin's lymphoma, MDS, NHL	phase 2
midostaurin (Novartis)	AML	phase 2
mifepristone (Corlux, Corcept)	brain cancer, endometrial cancer, prostate cancer, uterine leiomyoma	phase 2
milataxel (Taxolog)	breast cancer, colorectal cancer, NSCLC	phase 2
mitumprotimut-T (Specifid, Faville)	follicular lymphoma	phase 3
MK-0457 (Merck)	colorectal cancer, hematologic malignancies, NSCLC, solid tumors	phase 2
MK-0646 (Merck)	neuroendocrine tumors	phase 2
MK-0822 (Merck)	bone cancer	phase 2
MKC-1 (EntreMed)	breast cancer, NSCLC, pancreatic cancer	phase 2
MLN8237 (Millennium Pharmaceuticals)	AML, myelodysplastic syndromes, NHL	phase 2
MORAb-003 (Ludwig Institute for Cancer Research, Morphotek)	ovarian cancer	phase 2
MORAb-009 (Morphotek, NCI, U.S. Public Health Service)	mesothelioma, pancreatic cancer	phase 2
motesanib (Amgen)	breast cancer, thyroid cancer NSCLC	phase 2 phase 3
motexafin gadolinium (Xcytrin, Pharmacycics)	CLL, glioma, lymphoma, NHL, NSCLC, RCC	phase 2
MPC 6827 (Azixa, Myriad)	glioblastoma	phase 2
MVA-HPV-IL2 (R3484 (Roche)	cervical cancer	phase 2
neratinib (Wyeth)	breast cancer, NSCLC	phase 2
neuradiab (Bradmer)	glioblastoma	phase 2
nilotinib (Tasigna, Novartis)	CML GIST	phase 2 phase 3
nimo(tuzumab (YM Biosciences)	cervical cancer, esophageal cancer, hormone-refractory prostate cancer, pediatric glioma	phase 2
NKTR 102 (Nektar)	colorectal cancer, ovarian cancer	phase 2
nolatrexed (Thymitag, YM BioSciences)	colorectal cancer, head and neck cancer, lung cancer, pancreatic cancer, prostate cancer hepatocellular carcinoma	phase 2 phase 3
NOV-002 (Novelos)	breast cancer, ovarian cancer NSCLC	phase 2 phase 3
obatoxclax (Gemin X Biotechnologies)	follicular lymphoma, Hodgkin's lymphoma, MDS, myeloid leukemia	phase 2
oblimersen (Genasense, Genta)	AML, malignant melanoma breast cancer, NHL, solid tumors NSCLC	phase 3 phase 2 phase 2/3
octreotide (Oncolar, Novartis)	prostate cancer breast cancer	phase 2 phase 3

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
ofatumumab (GlaxoSmithKline)	CLL, NHL	phase 2/3
oglutamide (Implicit Bioscience)	ovarian cancer	phase 2
OGX-011 (Isis)	breast cancer	phase 2
omacetaxine mepesuccinate (ChemGenex)	AML, CML MDS	phase 2/3 phase 2
oncoVEX GM-CSF (BioVex)	malignant melanoma	phase 2
ONY-105 (Onyvax)	prostate cancer	phase 2
ONY-P (Onyvax)	prostate cancer	phase 2
oprelvekin (Neumega, Wyeth)	chemotherapy-induced mucositis	phase 2
oregovomab (OvaRex, ViRexx)	ovarian cancer	phase 3
ortataxel (Indena, Spectrum)	NHL, RCC, solid tumors	phase 2
ozarelix (Spectrum)	prostate cancer	phase 2
P276 (Piramal Life Sciences)	mantle-cell lymphoma	phase 2
paclitaxel poliglumex (Opaxio; Cell, Novartis)	NSCLC, ovarian peritoneal cancer	phase 3 phase 2
palifosfamide (Ziopharm Oncology)	sarcoma	phase 2
pamidronic acid (Aredia, Novartis)	multiple myeloma	phase 2
pancreatic cancer vaccine (GVAX Pancreatic, Cell Genesys)	pancreatic cancer	phase 2
panitumumab (Vectibix, Amgen)	head and neck cancer NSCLC	phase 2/3 phase 2
panobinostat (Novartis)	CML, cutaneous T-cell lymphoma AML, Hodgkin's lymphoma, prostate cancer	phase 2/3 phase 2
patupilone (Novartis)	brain cancer, breast cancer, hepatocellular carcinoma, NSCLC ovarian cancer	phase 2 phase 3
pazopanib (Armala, GlaxoSmithKline)	cervical cancer, fallopian tube cancer, glioma, NSCLC, ovarian cancer, peritoneal cancer breast cancer, RCC, sarcoma	phase 2 phase 3
PCI-24781 (Pharmacyclics)	hematological malignancies	phase 2
peginterferon alfa-2a (PEG-Intron A, Schering-Plough)	CML solid tumors	phase 3 phase 2
pelitinib (Wyeth)	colorectal cancer, NSCLC	phase 2
pelitrexol (Pfizer)	colorectal cancer, NSCLC	phase 2
pemetrexed (Alimta, Eli Lilly)	breast cancer, ovarian cancer, solid tumors head and neck cancers, SCLC	phase 2 phase 3
pentostatin (Nipent, Hospira)	CLL graft-versus-host disease NHL	phase 3 phase 2/3 phase 2
PEP 005 (Peplin)	actinic keratoses, basal cell cancer	phase 2
percutaneous hepatic perfusion doxorubicin (Delcath)	hepatocellular carcinoma	phase 2
perifosine (AEterna Zentaris, Keryx)	breast cancer, glioma, head and neck cancer, leukemia, malignant melanoma, multiple myeloma, pancreatic cancer, prostate cancer, RCC, sarcoma, Waldenstrom's macroglobulinemia	phase 2
pertuzumab (Omnitarg, Genentech)	breast cancer, ovarian cancer NSCLC	phase 3 phase 2
PF-299804	NSCLC	phase 2
PHA 739358 (Nerviano)	CML	phase 2
PHP (Curacyte)	malignant melanoma	phase 2
PI 88 (Progen)	hepatocellular carcinoma, malignant melanoma	phase 2
picoplatin (Ponard)	colorectal cancer, SCLC	phase 2
pixantrone (Cell Therapeutics)	NHL	phase 3
plerixafor (Genzyme)	stem cell mobilization	phase 3
plevitrexed (BTG Oncology)	ovarian cancer	phase 2
plitidepsin (Aplidin, PharmaMar)	multiple myeloma, prostate cancer, SCLC	phase 2
PN401 (Wellstat)	gastric cancer pancreatic cancer	phase 3 phase 2
polyphenon E (Polyphenon Pharma)	superficial bladder cancer	phase 2
polifeprosan (Gliadel Wafer, MGI)	brain metastasis	phase 2
polyphenon E (Polyphenon)	prostate intraepithelial neoplasia	phase 2
pomalidomide (Actimid, Celgene)	multiple myeloma, prostate cancer, sarcoma	phase 2
porfimer (Photofrin, PDT, Axcan)	cholangiocarcinoma	phase 2

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
PR1 cancer vaccine (Vaccine Company)	AML CML, MDS	phase 3 phase 2
pralatrexate (Allos)	B-cell lymphoma, bladder cancer, NHL, NSCLC, peripheral T-cell lymphoma	phase 2
prostate cancer vaccine (GVAX Prostate, Cell Genesys)	prostate cancer	phase 3
prostate cancer vaccine (Prostvac-VF, BN ImmunoTherapeutics)	prostate cancer	phase 2
PR-104 (Proacta)	NSCLC, SCLC	phase 2
PRX 302 (Protox)	prostate cancer	phase 2
PRX-321 (Protox)	glioblastoma	phase 2
PS-095760 (Ligand)	leukemia, NSCLC	phase 2
PV 10 (Provectus)	malignant melanoma	phase 2
PV 701 (Wellstat)	cervical cancer, colorectal cancer	phase 2
PX-12 (Oncothyreon)	pancreatic cancer	phase 2
quarflorin (Cylene)	CLL, neuroendocrine	phase 2
quinagolide (Norprolac, Ferring)	prolactinoma	phase 2
R1507 (Roche)	breast cancer, NSCLC, sarcoma	phase 2
R7159 (Roche)	hematologic malignancies	phase 2
R788 (Rigel)	B-cell lymphoma	phase 2
R851 (Takeda)	cervical dysplasia	phase 2
ranpirnase (Onconase; Alfacell, Strativa)	mesothelioma	phase 3
RAV-12 (Raven Biotechnologies)	pancreatic cancer	phase 2
recombinant vaccinia virus expressing PSA (Prostvac-VF, Therion)	prostate cancer	phase 2
relacatib (GlaxoSmithKline)	bone metastases	phase 2
reovirus (Reolysin, Oncolytics Biotech)	head and neck cancer, malignant melanoma, NSCLC, sarcoma	phase 2
retaspimycin (IPI-504, Infinity)	breast cancer, NSCLC GIST	phase 2 phase 3
rituximab (Rituxan; Biogen Idec, Genentech)	CLL, diffuse large B-cell lymphoma, NHL	phase 3
robatumumab (Schering-Plough)	colorectal cancer, osteosarcoma, sarcoma	phase 2
romidepsin (Gloucester)	cutaneous T-cell lymphoma, multiple myeloma, peripheral T-cell lymphoma, prostate cancer, RCC	phase 2
romiplostim (Nplate, Amgen)	MDS, thrombocytopenia	phase 2
RP-101 (SciClone)	pancreatic cancer	phase 2
RTA 402 (Reata)	malignant melanoma	phase 2
rubitecan (Orathecin, SuperGen)	breast cancer, CML, lung cancer, MDS, ovarian cancer pancreatic cancer	phase 2 phase 3
RX 0201 (Rexahn)	RCC	phase 2
S-1 (Sanofi-Aventis)	gastric cancer, pancreatic cancer, colorectal cancer NSCLC	phase 3 phase 2
sagopilone (Bayer)	brain cancer, breast cancer, prostate cancer	phase 2
salirasib (Concordia)	lung cancer	phase 2
samarium SM-153 lexidronam injection (Quadramet, Cytogen)	prostate cancer	phase 2
sapacitabine (Cyclacel)	ALL, cutaneous T-cell lymphoma, leukemia, MDS, NSCLC	phase 2
SAR109659 (TroVax; BioMedica, Sanofi-Aventis)	RCC	phase 3
saracatinib (AstraZeneca)	metastatic bone cancer	phase 2
sardomozide (Novartis)	NHL	phase 2
sargramostim (Leukine, Bayer)	malignant melanoma CLL, NHL, ovarian cancer, prostate cancer	phase 3 phase 2
satraplatin (Spectrum)	breast cancer, NSCLC prostate cancer	phase 2 phase 3
SCH 58500 (Schering-Plough)	NSCLC	phase 2
SCH 727965 (Schering-Plough)	breast cancer, NSCLC	phase 2
seliciclib (Cyclacel)	nasopharyngeal, NSCLC	phase 2
SGN-30 (Seattle Genetics)	cutaneous T-cell lymphoma, Hodgkin's lymphoma	phase 2
SGN-35 (Seattle Genetics)	Hodgkin's lymphoma	phase 2
sirotuzumab (Life Science)	colorectal cancer, head and neck cancer, lung cancer	phase 2
sipuleucel-T (Provenge, Dendreon)	nonmetastatic androgen-dependent prostate cancer	phase 3
sirolimus (Rapamune, Wyeth)	bone marrow transplant rejection	phase 2

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
SNDX-275 (Syndax Pharmaceuticals)	breast cancer	phase 2
SNS 595 (Sunesis)	AML, NSCLC, ovarian cancer, SCLC	phase 2
sorafenib (Nexavar; Bayer, Onyx)	breast cancer, SCLC, solid tumors malignant melanoma, NSCLC	phase 2 phase 3
SU-14813 (Pfizer)	breast cancer	phase 2
sunitinib (Sutent; Pfizer)	breast cancer, hepatocellular carcinoma, NSCLC, pancreatic cancer colorectal cancer, gastric cancer, hormone-refractory prostate cancer, neuroendocrine tumors, sarcoma, solid tumors	phase 3 phase 2
systemic hedgehog antagonist (Genentech)	basal cell cancer, colorectal cancer, ovarian cancer	phase 2
T4N5 liposome lotion (Dimericine, AGI Dermatics)	melanoma	phase 2
tacrolimus (Prograf, Astellas)	bone marrow transplant rejection	phase 3
TAK-851 (Millennium Pharmaceuticals)	cervical dysplasia	phase 2
talactoferrin (Agenrix)	NSCLC, RCC	phase 2
talampel (Teva)	glioblastoma	phase 2
talaporfin (Libx, Light Sciences)	colorectal cancer	phase 3
tamibarotene (Innovive)	acute promyelocytic leukemia	phase 2
tandutinib (Millenium)	AML, glioma, prostate cancer	phase 2
tanespimycin (Kosan)	breast cancer, solid tumors multiple myeloma	phase 2 phase 3
TAS-102 (Taiho)	gastric cancer	phase 2
TAS-106 (Taiho)	head and neck cancer	phase 2
TAS-108 (Taiho)	breast cancer	phase 2
TAS-109 (Taiho)	colorectal cancer	phase 2
tasitulum (Eli Lilly)	malignant melanoma, ovarian cancer, soft tissue sarcoma	phase 2
tegafur/uracil (Merck KGaA)	colorectal cancer head and neck cancer	phase 3 phase 2
temozolomide (Temodar, Schering-Plough)	AML, sarcoma, SCLC, solid tumors	phase 2
temsirolimus (Torisel, Wyeth)	colorectal cancer, multiple myeloma, NSCLC, prostate cancer mantle cell lymphoma, RCC	phase 2 phase 3
terameprocol (Erimos)	cervical intraepithelial neoplasia	phase 2
tesetaxel (Genta)	colorectal cancer, stomach cancer	phase 2
tesmilifene (YM Biosciences)	breast cancer prostate cancer	phase 3 phase 2
tetrandrine (Millenia Hope)	colorectal cancer	phase 3
TG 1042 (Transgene)	cutaneous B-cell lymphoma	phase 2
TG4001 (Roche)	cervical intraepithelial neoplasia	phase 2
thymalfasin (Zadaxin, SciClone)	malignant melanoma	phase 2
tigapotide (Ambrilia Biopharma)	prostate cancer	phase 2
tigatuxumab (Daiichi Sankyo)	pancreatic cancer	phase 2
tipifarnib (Zarnestra, Johnson & Johnson)	AML, pancreatic cancer glioblastoma	phase 3 phase 2
ticilimumab (Pfizer)	colorectal cancer, hepatocellular carcinoma, NSCLC, prostate cancer malignant melanoma	phase 2 phase 3
tirapazamine (SRI International)	cervical cancer	phase 3
TJ9 (Tsumura)	liver cancer	phase 2
TM-601-131 (Trans Molecular)	glioma	phase 2
TNFrade (GenVec)	colorectal cancer pancreatic cancer	phase 2 phase 3
topotecan (Hycamtin, GlaxoSmithKline)	breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, NHL, pancreatic cancer, prostate cancer, uterine cancer ovarian cancer, preleukemia	phase 2 phase 3
toremifene (Acapodene, GTx)	prostate cancer prevention, prostatic intraepithelial neoplasia	phase 3
tositumumab (Bexxar, GlaxoSmithKline)	lymphoma, myeloablation	phase 2
TPI 287 (Tapestry)	hormone-refractory prostate cancer, pancreatic cancer	phase 2
trabectedin (Yondelis, Johnson & Johnson)	breast cancer, endometrial cancer, prostate cancer ovarian cancer, sarcoma	phase 2 phase 3
transgenic B lymphocyte immunotherapy (Cosmo Bioscience)	prostate cancer	phase 2
trastuzumab (Herceptin, Genentech)	colorectal cancer, pancreatic cancer, prostate cancer, ovarian cancer, salivary gland cancer esophageal cancer, gastric cancer	phase 2 phase 3

Focus on Drugs in the Pipeline

Generic name	Indication	Development status
trastuzumab-DM1 (Genentech)	breast cancer	phase 3
tremelimumab (Pfizer)	colorectal cancer, malignant melanoma, NSCLC, prostate cancer	phase 2
trilostane (Genzyme)	breast cancer, prostate cancer	phase 2
triptorelin (Watson)	breast cancer	phase 3
troxacitabine (Troxatyl, SGX)	pancreatic cancer	phase 2
tucotuzumab celmoleukin (EMD Lexigen)	colorectal cancer, NSCLC, ovarian cancer, prostate cancer, SCLC	phase 2
tumor-targeted gene therapy (Rexin-G, Epeius)	osteosarcoma, sarcoma	phase 2
ursodeoxycholic acid (Urso Forte, Axcen)	colorectal cancer	phase 2
V503 (Merck)	cervical cancer prevention	phase 3
V505 (Merck)	cervical cancer	phase 3
V935 (Merck)	solid tumors	phase 3
vandetanib (Zactima, AstraZeneca)	breast cancer, medullary thyroid cancer, multiple myeloma, SCLC, solid tumors NSCLC	phase 2 phase 3
vatalanib (Novartis)	colorectal cancer glioblastoma	phase 3 phase 2
Vaxico (Ablvax, Breakthrough Therapeutics)	CML	phase 2
VB 4845 (Viventia Biotech)	bladder cancer, head and neck cancer	phase 2
velimogene aliplasimid (AlloVectin-7, Vical)	metastatic melanoma	phase 3
vincristine liposomal (Marqibo, Hana Biosciences)	ALL, malignant melanoma, NHL	phase 2
vinflunine (Pierre Fabre)	bladder cancer, breast cancer, urogenital cancer	phase 2
vinorelbine (Novacea)	breast cancer, ovarian cancer cervical cancer, malignant melanoma, prostate cancer	phase 3 phase 2
virulizin (Virulizin, Lorus)	pancreatic cancer	phase 3
vitespen (Oncophage, Antigenics)	colorectal cancer, glioma, RCC malignant melanoma	phase 2 phase 3
volociximab (PDL BioPharma, Biogen Idec)	malignant melanoma, NSCLC, ovarian cancer, pancreatic cancer, RCC	phase 2
vorinostat (Zolinza, Merck)	AML, B-cell lymphoma, breast cancer, glioblastoma, head and neck cancer, lymphoma, MDS mesothelioma	phase 2 phase 3
VP 101 (Virium)	glioblastoma, colorectal cancer, hematologic malignancies, prostate cancer	phase 2
W-G250 (Rencarex, Willex)	RCC	phase 3
WX-671 (Willex)	breast cancer	phase 2
xaliproden (Sanofi-Aventis)	chemotherapy-induced neuropathies	phase 3
XL184 (Exelixis)	glioblastoma medullary thyroid cancer	phase 3 phase 2
XL-647 (Exelixis)	NSCLC	phase 2
XL880 (Exelixis)	gastric cancer, head and neck cancer, RCC	phase 2
XRP6258 (Sanofi Aventis)	prostate cancer	phase 3
XRP6258/lorotaxel (Sanofi Aventis)	breast cancer	phase 2
YM 155 (Astellas)	metastatic diffuse B-cell lymphoma, hormone-refractory prostate cancer, solid tumors	phase 2
YMB2002 (YM Biosciences)	prostate cancer	phase 2
zalutumumab (HuMAX-EGFr, Genmab)	colorectal cancer, NSCLC	phase 2
zanolimumab (HuMAX-CD4; Genmab)	T-cell lymphoma	phase 3
ZD4054 (AstraZeneca)	hormone-refractory prostate cancer	phase 3
zosuquidar (Kanisla)	AML	phase 3

Information in this chart was gathered from the Pharmaceutical Research and Manufacturers of America, corporate websites and the databases of HEM/ONC TODAY. The publisher or editors do not assume responsibility for any errors or omissions.